EC approves GSK's albiglutide

The European Commission approved Eperzan albiglutide from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat Type II diabetes as monotherapy or as add-on therapy. Eperzan is a once-weekly, glucagon-like...